Orchid Chemicals & Pharmaceuticals is currently trading at Rs. 55.65, up by 2.05 points or 3.82% from its previous closing of Rs. 53.60 on the BSE.
The scrip opened at Rs. 55.90 and has touched a high and low of Rs. 57.80 and Rs. 54.80 respectively. So far 386516 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 78.25 on 19-Mar-2013 and a 52 week low of Rs. 35.00 on 06-Aug-2013.
Last one week high and low of the scrip stood at Rs. 57.80 and Rs. 47.40 respectively. The current market cap of the company is Rs. 390.30 crore.
The promoters holding in the company stood at 32.28% while Institutions and Non-Institutions held 7.83% and 55.31% respectively.
Orchid Chemicals & Pharmaceuticals is planning to repay Rs 700 crore of debt from the Rs 1300 crore Hospira to the lenders, which the company is expecting to conclude by April. The Corporate Debt Restructuring (CDR) Empowered Group has issued the letter of approval for debt restructuring package on March 10. According to the terms of debt restructuring, the company will sell and transfer its penicillin and penems (including carbapenems) active pharmaceutical ingredient business together with its manufacturing facilities at Aurangabad, Maharashtra and associated research and development facility at Sholinganallur, Chennai.
From the sale proceeds, company will repay part of its debt, amounting to Rs 700 crore, to the lenders, while rest of the debt Rs 2,866 crore will be restructured. The restructured debt together with funded loans would have to be repaid over 8 years starting from April 2015.
Orchid Chemicals & Pharmaceuticals is a pharmaceutical company engaged in development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. The company was incorporated in the year 1992 as a 100% export-oriented unit (EOU).
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1520.00 |
| Dr. Reddys Lab | 6050.00 |
| Cipla | 1383.40 |
| Zydus Lifesciences | 1006.10 |
| Lupin | 1616.90 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
